Stock ARDS ARIDIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Delayed OTC Markets
Other stock markets
 17:41:13 10/05/2024 BST 		5-day change 1st Jan Change
0.0663 USD +12.37% Intraday chart for Aridis Pharmaceuticals, Inc. +7.80% -5.42%
2023 Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023. CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Aridis Pharmaceuticals' Price Target to $10 From $19, Keeps Buy Rating
MT
Maxim Downgrades Aridis Pharmaceuticals to Hold From Buy
MT
Northland Securities Adjusts Aridis Pharmaceuticals PT to $10 From $22, Maintains Outperform Rating
MT
ARIDIS PHARMACEUTICALS : HC Wainwright Adjusts Aridis Pharmaceuticals' Price Target to $19 From $11, Reiterates Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARDS Stock
  4. News Aridis Pharmaceuticals, Inc.
  5. Analyst Reco.